XPO1 Antibody, HRP conjugated

1. We describe three in vitro reconstituted disassembly intermediates, which show binding of a Crm1 export complex via two FG-repeat patches, cargo-release by RanBP2's Ran-binding domains and retention of free Crm1 at RanBP2 after Ran-GTP hydrolysis. PMID:27160050
2. Nuclear entrapment of p33ING1b by inhibition of exportin-1 triggers apoptosis in head and neck squamous cell cancer cells. PMID:29729696
3. CDK4 and XPO1 are not altered in a rare undifferentiated sarcoma, making them therapeutic targets PMID:27329820
4. The subcellular distributions of IkappaB and NFkappaB are indicative of carcinogenesis. Inhibition of XPO1 results in intranuclear retention of IkappaB, which inhibits NFkappaB and thereby provides a novel mechanism for drug therapy in sarcoma. This effect can be further enhanced in relatively selinexor-resistant sarcoma cell lines by pretreatment with the proteasome inhibitor carfilzomib. PMID:28314790
5. this work advocates for assessing 2p+ and XPO1 mutations before choosing a chronic lymphocytic leukemia therapy. PMID:28344316
6. Importin-beta and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function. PMID:28600321
7. We provide evidence for a regulatory role of CRM1 (chromosome-region-maintenance-1; also known as XPO1, exportin-1) in juxta-nuclear microtubule-dependent adenovirus transport. Leptomycin B (LMB) abolishes nuclear targeting of adenovirus. It binds to CRM1, precludes CRM1-cargo binding and blocks signal-dependent nuclear export. PMID:28515232
8. in leukemia cell lines an XPO1 heterozygous mutation confers similar resistance against selinexor as homozygous substitution, demonstrating that SINE resistance can be obtained by a single and dominant mutation of the cysteine528 residue in XPO1 PMID:27634897
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. PMID:27806331
10. KPT-8602 is highly specific for XPO1 inhibition and demonstrates potent anti-leukemic activity supporting clinical application of the second-generation SINE compound for the treatment of Acute Lymphoblastic Leukemia PMID:27780859
11. Taken together, these results provide evidence that XPO1 inhibition represents a new therapeutic strategy for overcoming platinum resistance in women with ovarian cancer PMID:27649553
12. Selinexor, a selective inhibitor of XPO1, is currently being tested as single agent in clinical trials in acute myeloid leukemia. PMID:27358488
13. Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals. PMID:28282025
14. These results suggest a differential interaction between human Crm1 and mouse Crm1 and many lentiviral Rev proteins, which may partially explain the HIV replicative defect in mice. PMID:29028476
15. Combined targeting of XPO1 and ERalpha in several tamoxifen-resistant cell lines and tumor xenografts with the XPO1 inhibitor, Selinexor, and tamoxifen restored tamoxifen sensitivity and prevented recurrence in vivo. PMID:27533791
16. Results suggest that the cancer-inhibitory activity of sodium butyrate and its derivatives on liver carcinogenesis may be attributed to retention of p53 and CRM1 proteins in the nucleus, an event that may trigger activation of p53-mediated apoptotic cell death in neoplastic cells. PMID:27013579
17. REVIEW: the role of XPO1 in B cell hematological malignancies PMID:28196522
18. Selinexor, an inhibitor of XPO1, induces cell cycle arrest independent of alterations in the KIT signaling pathway. PMID:26918731
19. Authors investigated the clinical significance of XPO1 mutations in patients with CLL. PMID:27468087
20. Here, the authors identify cellular nuclear transport factor 2 (NTF2)-like export protein 1 (NXT1) as a novel binding partner of nucleoprotein (NP) that stimulates NP-mediated nuclear export via the CRM1-dependent pathway. PMID:27483302
21. Data show that the cytoplasmic localization of promyelocytic leukaemia (PML) is mediated by its nuclear export in a chromosomal maintenance 1 (CRM1)-dependent manner. PMID:26549027
22. CRM1 and CDK5 co-expression was an independent prognostic factors for gastric cancer (GC). Combined CRM1 and CDK5 expression could provide a prognostic model for overall survival of GC. PMID:28373767
23. Anti-tumor activity of selective exportin 1 inhibitors is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. PMID:27693556
24. the functional consequences of a recurrent cancer-related mutation, which targets a residue near CRM1 NES-binding cleft, was investigated. PMID:27312238
25. we characterized the biologic significance of CRM1 in the context of Ewing sarcoma and determined the therapeutic merit of CRM1 inhibition for this malignancy. PMID:26956669
26. XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein PMID:27312795
27. CRM1 mediates nuclear export of influenza A nucleoprotein. PMID:28399435
28. the detection of the XPO1 E571K mutation in biopsy and plasma cell-free DNA by digital PCR may be used as a novel biomarker in classical Hodgkin lymphoma for both diagnosis and minimal residual disease, and pinpoints a crucial role of XPO1 in classical Hodgkin lymphoma pathogenesis. PMID:27479820
29. The study demonstrated the association of NUP98-IQCG with CRM1, and found that NUP98-IQCG expression inhibits the CRM1-mediated nuclear export of p65 and enhances the transcriptional activity of nuclear factor-kappaB. Moreover, IQCG could be entrapped in the nucleus by NUP98-IQCG, and the fusion protein interacts with calmodulin via the IQ motif in a calcium-independent manner. PMID:27864780
30. XPO1 inhibition has downstream effects on the 3D nuclear organization of the genome. PMID:26991404
31. findings suggest that mitotic abnormalities can be prevented by the modulation of CRM1 and survivin. We demonstrated the ability of compound 'IV08.009' to efficiently protect cultured keratinocytes from mitotic abnormalities PMID:26859314
32. the interplay between CRM-1 and p27Kip1 may provide potentially potent biomarkers and functional targets for the development of future cholangiocarcinoma treatments. PMID:27279267
33. Data show that functional Exportin 1 (XPO1/CRM1) inhibition correlates to XPO1 occupancy by selinexor in U2OS cells. PMID:26654943
34. The results indicate that highly selective targeting of Nup98-fusion proteins to Hox cluster regions via prebound Crm1 induces the formation of higher order chromatin structures that causes aberrant Hox gene regulation. PMID:26740045
35. Together, our study identifies CRM1 as a valid target in ovarian cancer and provides a basis for the development of S109 in ovarian cancer. PMID:26055813
36. this regulation was conserved in HIV-2 and was dependent on the CRM1-dependent nuclear export pathway suggesting a role of the RNA helicase in interconnecting nuclear export with ribosome recruitment of the viral unspliced mRNA PMID:27012366
37. HIV-1 depends on host-cell-encoded factors to complete its life cycle; data suggest nucleus-located NAF1 (HIV Nef-associated factor 1) promotes nuclear export of un-spliced HIV-1 gag mRNA; association between NAF1 and CRM1 is required for this function. PMID:26733199
38. The binding of nuclear export signals to CRM1 in both orientations results in a large expansion in nuclear export signal consensus patterns and therefore a corresponding expansion of potential nuclear export signals in the proteome. PMID:26349033
39. Findings indicate that exportin 1 protein (CRM1) is a valid target for the treatment of colorectal cancer. PMID:25996664
40. our results elucidate that RanGAP1 is actively transported between the nuclear and cytoplasmic compartments, and that the cytoplasmic and NPC localization of RanGAP1 is dependent on CRM1-mediated nuclear export. PMID:26506250
41. Ribosomal biogenesis appears to be a key component through which XPO1 contributes to tumor cell survival. PMID:26340096
42. review of physiological function of chromosome region maintenance 1 protein. PMID:26048327
43. Our study suggests SINE-mediated XPO1/CRM1 inhibition as a novel therapeutic option for DMPM. PMID:25948791
44. These data suggest that CRM1 plays an important role in lung carcinogenesis. PMID:25629636
45. The export receptor Crm1 forms a dimer to promote nuclear export of HIV RNA. PMID:25486595
46. This study identifies a cellular protein named RBM14 that is associated with XPO1 (CRM1), a nuclear protein that binds to the HIV-1 Rev protein and mediates nuclear export of incompletely spliced HIV-1 viral RNAs PMID:25589658
47. The new CRM1 inhibitors, therefore, hold strong potential and warrant further clinical investigations for PDAC. PMID:24899509
48. CRM1 has a role in regulating HOXA gene transcription in CALM-AF10 leukemias PMID:25027513
49. Studied CRM1 expression in esophageal squamous cell carcinoma; statistical analysis demonstrated that patients with high CRM1 levels indicated shorter survival period. We further found that silencing CRM1 caused apoptosis in ESCC cell lines. PMID:25148895
50. CRM1 as a new therapeutic target for non-Hodgkin lymphoma. PMID:25466285

Show More

Hide All

HGNC: 12825

UNIGENE: Hs.370770

KEGG: hsa:7514

STRING: 9606.ENSP00000384863

OMIM: 602559